P
Peter C Gøtzsche
Researcher at Cochrane Collaboration
Publications - 426
Citations - 191584
Peter C Gøtzsche is an academic researcher from Cochrane Collaboration. The author has contributed to research in topics: Clinical trial & Systematic review. The author has an hindex of 90, co-authored 413 publications receiving 147009 citations. Previous affiliations of Peter C Gøtzsche include University of Copenhagen & Copenhagen University Hospital.
Papers
More filters
Journal ArticleDOI
Erratum to: “CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials” [J Clin Epidemiol 2010;63(8):e1–37]
David Moher,Sally Hopewell,Kenneth F. Schulz,Victor M. Montori,Peter C Gøtzsche,Philip J. Devereaux,Diana Elbourne,Matthias Egger,Douglas G. Altman +8 more
Journal ArticleDOI
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials
Julie Pildal,Asbjørn Hróbjartsson,Karsten Juhl Jørgensen,Jørgen Hilden,Douglas G. Altman,Peter C Gøtzsche +5 more
TL;DR: Two-thirds of conclusions in favour of one of the interventions were no longer supported if only trials with adequate allocation concealment were included, and the loss of support mainly reflected loss of power and a shift in the point estimate towards a less beneficial effect.
Journal ArticleDOI
Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention
TL;DR: Spontaneous improvement and effect of placebo contributed importantly to the observed treatment effect in actively treated patients, but the relative importance of these factors differed according to clinical condition and intervention.
Journal ArticleDOI
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review
TL;DR: Industry supported reviews of drugs should be read with caution as they were less transparent, had few reservations about methodological limitations of the included trials, and had more favourable conclusions than the corresponding Cochrane reviews.
Journal ArticleDOI
Non-steroidal anti-inflammatory drugs.
TL;DR: Bias is common in the design and analysis of the trials, to such an extent that a systematic review identified false significant findings favouring new drugs over control drugs in 6% of trials.